-
Innovation Ranking
Innovation Ranking – JL Mag Rare-Earth Co Ltd
Jlmag Rare-Earth Co Ltd (Jlmag) is a manufacturer of rare earth permanent magnetic materials. The company engaged in the research and development, production, and sale of permanent magnetic materials. It provides various grades of NdFeB magnets. Jlmag also provides R&D equipment that comprises MPS Permagraph, salt spray test chamber, vacuum melting furnace, wire cutting machines and flux meters. The company’s products are used in wind power, new energy vehicles, inverter air conditioners, energy-saving elevators and other industrial energy-saving motors. It...
-
Thematic Analysis
Rare Disease ​Pipeline Analysis ​Landscape, 2023
This report investigates the Rare Disease ​Pipeline Analysis ​Landscape in 2023 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize these trends within your sector.
-
Product Insights
Likelihood of Approval Analysis for Ocular Melanoma
Overview How likely is it that the drugs in Ocular Melanoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocular Melanoma Overview Ocular melanoma is an extremely rare form of cancer...
-
Product Insights
Likelihood of Approval Analysis for Mesenchymal Tumor Of The Gastrointestinal Tract
Overview How likely is it that the drugs in Mesenchymal Tumor Of The Gastrointestinal Tract will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mesenchymal Tumor Of The Gastrointestinal Tract Overview Mesenchymal...
-
Product Insights
Likelihood of Approval Analysis for Natural Killer Cell Lymphomas
Overview How likely is it that the drugs in Natural Killer Cell Lymphomas will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Natural Killer Cell Lymphomas Overview Natural killer (NK) cell lymphomas...
-
Product Insights
Likelihood of Approval Analysis for Mycosis Fungoides
Overview How likely is it that the drugs in Mycosis Fungoides will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mycosis Fungoides Overview Mycosis fungoides is a rare type of non-Hodgkin lymphoma,...
-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Friedreich Ataxia (FRDA) Marketed and Pipeline Drugs Report Overview Friedreich's Ataxia (FRDA) is a rare, genetic disorder. It is progressive and typically manifests between the ages of 10 and 15. The disorder is characterized by a gradual decline in coordination, muscle strength, and endurance. Individuals with FRDA often become reliant on wheelchairs as the condition advances. The Friedreich Ataxia (FRDA) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast,...
-
Product Insights
Likelihood of Approval Analysis for Retinal Degeneration
Overview How likely is it that the drugs in Retinal Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retinal Degeneration Overview Retinal degeneration refers to a group of diseases that...
-
Product Insights
Likelihood of Approval Analysis for Vaginal Cancer
Overview How likely is it that the drugs in Vaginal Cancer will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vaginal Cancer Overview Vaginal cancer is a rare cancer that occurs in...
-
Product Insights
Likelihood of Approval Analysis for Systemic Sclerosis (Scleroderma)
Overview How likely is it that the drugs in Systemic Sclerosis (Scleroderma) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Systemic Sclerosis (Scleroderma) Overview Scleroderma is a group of rare diseases...